Medicenna Therapeutics Corp. (MDNA) Sets Oral Presentation of MDNA11 Topline Data at SITC 2026

Medicenna Therapeutics (MDNA) will present Phase 1/2 data for MDNA11 at SITC 2026, showing activity in biomarker-enriched GI cancers, including ICI-refractory cases. The presentation highlights monotherapy and combination therapy results.

Original reporting
Published Oct 5, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medicenna Therapeutics Corp. (MDNA) Sets Oral Presentation of MDNA11 Topline Data at SITC 2026 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upcoming SITC presentation is the first public hint of efficacy, safety, and combination potential for MDNA11.

02

Market read

Biotech investors will watch the SITC data release closely; positive results could trigger a short‑term rally.

03

What to watch

Potential competition from other cytokine therapies and regulatory timelines.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Medicenna Therapeutics (MDNA) is a clinical‑stage biotech developing IL‑2 Superkine therapies for GI cancers.

Market effects

May boost sentiment for IL‑2 based immunotherapies and related biotech peers.

Limited to US biotech sector.

Low; relevance confined to investors tracking early‑stage cancer immunotherapy pipelines.

Counterpoint

If data are modest, the hype could reverse, leading to a sell‑off.

Key entities

  • Medicenna Therapeutics Corp.

    Developer of IL‑2 Superkine immunotherapy candidates.

Related articles

$NNVCMed

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

$UBERMed

Kohl’s products now available for delivery on Uber Eats

Uber (UBER) and Kohl's (KSS) partnered to offer Kohl's products via Uber Eats, covering 1,100+ U.S. stores. Items include apparel, home goods, and Sephora beauty products. The service launches before the holiday season, with a $10 discount on first orders over $50 until December 3, 2026. Kohl's operates 1,100+ stores in 49 states.

$SPCBMed

SuperCom Wins 2nd Electronic Monitoring Contract in Indiana, Fully Displacing Incumbent Provider

SuperCom (SPCB) won its second electronic monitoring contract in Indiana, replacing an incumbent provider. The deal involves deploying its PureSecurity suite, with rollout starting in December 2026. The company reported a trailing twelve-month EBITDA of approximately $12.1 million through Q3 2026, citing over 50 new U.S. contracts and 20 national project wins in Europe since mid-2024.